ONWARD Medical NV's ARC-BCI system receives FDA TAP acceptance and Breakthrough Device Designation.

ONWARD Medical NV's ARC-BCI system has been accepted into the US FDA's Total Product Lifecycle Advisory Program (TAP). This acceptance follows the company's announcement last week of receiving FDA Breakthrough Device Designation for the ARC-BCI System. ONWARD is one of the first brain-computer interface entrants in the program, aimed at optimizing the commercialization pathway for breakthrough medical technologies.